

# ForPatients

by Roche

Solid Tumors

## A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors

**Trial Status**  
Completed

**Trial Runs In**  
5 Countries

**Trial Identifier**  
NCT04857138 2020-004489-21  
WP42627

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

A study to evaluate the safety, pharmacokinetics and anti-tumor activity of RO7300490 as a single agent or in combination with atezolizumab. The study will consist of 3 parts: [Part 1] Dose-Escalation of RO7300490 as a single agent; [Part 2] Dose-Escalation of RO7300490 in combination with atezolizumab and [Part 3] Dose-Expansion of RO7300490 in combination with atezolizumab in selected cancer types.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT04857138 2020-004489-21 WP42627**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---